New Antibody Stops Aggressive Prostate Cancer Spread

A breakthrough antibody developed by researchers at Umeå University has successfully halted the growth and spread of aggressive prostate cancer in preclinical testing, offering new hope for patients facing the deadliest form of the disease.

The experimental drug represents years of dedicated work by Professor Maréne Landström and her team. They created a fully human antibody, meaning it's made entirely from human proteins rather than animal sources, which typically makes treatments safer and more effective.

When prostate cancer turns aggressive, it spreads beyond the prostate to lymph nodes and bones, becoming life threatening. This new antibody specifically targets that dangerous spreading process, stopping tumors from growing and preventing them from metastasizing in laboratory studies.

What makes this treatment especially promising is its novel mechanism. The antibody works differently than existing cancer drugs, which the researchers believe could mean fewer side effects for patients down the road.

"We are very pleased and proud that we have been able to identify the mechanisms that drive cancer cell growth, invasiveness, and metastatic spread," says Landström. The team published their findings in the journal Signal Transduction and Targeted Therapy.

The work required collaboration across multiple organizations. Drug development specialists at SciLifeLab helped create the antibody, while the Umeå Biotech Incubator and MetaCurUm Biotech AB provided crucial support and funding.

The Ripple Effect

This discovery could extend far beyond prostate cancer. The research team is already planning to test whether the same treatment approach could work against other solid tumors, potentially opening doors for patients fighting different cancers.

The antibody still faces important hurdles before reaching patients. Additional safety studies are required, followed by regulatory approval in Europe or the United States, a process that typically takes several years.

But the successful preclinical results mark a major milestone. The treatment performed exactly as the researchers hoped, proving their theory about how to stop aggressive cancer spread.

For men diagnosed with advanced prostate cancer, this research offers something invaluable: a potential new weapon in the fight for survival and quality of life. The project received funding from major organizations including the Knut and Alice Wallenberg Foundation, the Swedish Cancer Society, and the Swedish Research Council, reflecting confidence in its promise.

The next chapter of testing will reveal whether this innovative approach can deliver on its early potential and bring a safer, more effective treatment to patients who need it most.